Quince Therapeutics
QNCX
27 hedge funds and large institutions have $17.3M invested in Quince Therapeutics in 2026 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 29 closing their positions.
1,099% more capital invested
Capital invested by funds: $1.44M → $17.3M (+$15.9M)
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
61% more call options, than puts
Call options by funds: $3.46M | Put options by funds: $2.14M
1.96% more ownership
Funds ownership: 0.07% → 2.02% (+2%)
37% less funds holding
Funds holding: 43 → 27 (-16)
55% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.66M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.61M |
| 3 |
Millennium Management
New York
|
+$1.34M |
| 4 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
+$928K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$320K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$527K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$176K |
| 3 |
IC
IEQ Capital
Foster City,
California
|
-$60.9K |
| 4 |
State Street
Boston,
Massachusetts
|
-$25.1K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$19.8K |
QNCX Hedge Fund Activity: Q2 2026 in Review
27 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q2 2026, worth a combined $17.3M — up 1,099% from $1.44M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of QNCX and 13 opened new positions — a net loss of 16 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $1.66M. The largest seller was Woodline Partners, exiting entirely with an estimated $527K sold.
- 27 institutional investors held Quince Therapeutics (QNCX) as of Q2 2026, down from 43 in Q1 2026.
- Funds reported $17.3M of Quince Therapeutics stock for Q2 2026, up 1,099% quarter-over-quarter.
- 13 funds opened new Quince Therapeutics positions in Q2 2026 and 29 closed out, a net change of -16 holders.
- The largest Quince Therapeutics buyer in Q2 2026 was Ikarian Capital, an estimated $1.66M added.
- The largest Quince Therapeutics seller in Q2 2026 was Woodline Partners, an estimated $527K sold.
Based on aggregated 13F filings for Q2 2026.